Five Fallen Biotech Stocks We're Watching for Rebounds

Edward Kim  |

Image source: Chokniti Khongchum / Pixabay

Biotech investors have generally been on the wrong end of the trade in 2022, with poor absolute performance and relative performance that lags the market.

The Nasdaq Biotechnology Index is off 19.2% year-to-date, compared to an 18.7% decline for the Nasdaq Composite and a 10.6% loss for the S&P 500 Index.

In an environment where the megacap technology stocks lead the market in both directions, we think investors who are willing to take the time to do a little research can find opportunities in biotech and life sciences, particularly at the smaller end of the market cap spectrum.

We highlight five today that we're watching for potential rebounds over the next 12 months:

 

Innate Pharma

Stocks To Watch in 5G Wireless Growth Wave

IPHA)

 

BioXcel TherapeuticsBTAI)

 

Editas MedicineEDIT)

 

AffimedAFMD)

 

GenfitGNFT)

 

Which companies are you following, biotech or otherwise? Let us know, and we promise to write about several of the submissions. Please email us at editor@equities.com.

Thank you.

_____

Source: Equities News

 

 

 

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings
DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter
Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility

Market Movers

Sponsored Financial Content